Serous Cystadenocarcinoma

A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Also Known As:
Cystadenocarcinoma, Serous; Cystadenocarcinomas, Serous; Serous Cystadenocarcinomas
Networked: 165 relevant articles (3 outcomes, 12 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Ascites
2. Ovarian Neoplasms (Ovarian Cancer)
3. Mucinous Cystadenocarcinoma
4. Neoplasms (Cancer)
5. Endometrioid Carcinoma


1. Huang, Yan: 2 articles (01/2015 - 07/2008)
2. Gao, Yutao: 2 articles (09/2014 - 09/2014)
3. Chu, Simon: 2 articles (07/2013 - 03/2002)
4. Fuller, Peter J: 2 articles (07/2013 - 03/2002)
5. Ren, Fang: 2 articles (01/2013 - 11/2011)
6. Chao, Tai-Kuang: 2 articles (06/2012 - 03/2009)
7. Lin, Chih-kung: 2 articles (06/2012 - 01/2008)
8. Wertel, Iwona: 2 articles (06/2011 - 01/2011)
9. Jin, Jong-Shiaw: 2 articles (03/2009 - 01/2008)
10. Yang, Ying: 2 articles (07/2007 - 06/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Serous Cystadenocarcinoma:
1. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
2. Cisplatin (Platino)FDA LinkGeneric
3. Proteins (Proteins, Gene)IBA
03/01/1988 - "A primary culture of serous cystadenocarcinoma of the ovary was used to study the expression of intermediate filament proteins and the deposition of basal lamina proteins. "
09/01/2001 - "Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis."
06/01/2007 - "Restriction fragment differential display polymerase chain reaction (RFDD-PCR), semi-quantitative RT-PCR and immunohistochemical staining were applied to analyze the differentially expressed genes and proteins of ubiquitin specific proteases (USPs), USP2 and USP14, and ubiquitin factor E4A (UBE4A) between ovarian serous cystadenocarcinoma and adjacent normal tissues obtained from 40 patients aged from 29 to 72 years old, collected in 2005 year at excision of surgical operation with ovarian serous cystadenocarcinoma. "
09/01/2014 - "In this study, on the basis of comprehensive bioinformatic analyses, including mRNA expression according to microarray data, protein/gene interaction, protein-small molecule interaction, annotation of biological process and microRNA-mRNA interaction analysis, we revealed that the NEK11 mRNA was significantly downregulated in 586 cases of ovarian serous cystadenocarcinomas and cisplatin-resistant A2780 ovarian cancer cells, and interacted with 22 proteins and 4 small molecules which all were contributed to drug resistance in ovarian cancer. "
01/01/1982 - "By using an immunoglobulin-enzyme bridge method, pregnancy-specific beta 1-glycoprotein (SP1) and placenta-specific tissue proteins (PP5, PP10, PP11, PP12) were investigated in 15 cases of mucinous cystadenocarcinoma and 20 cases of serous cystadenocarcinoma. "
4. Calmodulin (Calcium-Dependent Activator Protein)IBA
5. Messenger RNA (mRNA)IBA
6. ParaffinIBA
7. MicroRNAs (MicroRNA)IBA
8. Formaldehyde (Formol)FDA Link
9. Collagen Type IV (Type IV Collagen)IBA
10. Interleukin-17 (Interleukin 27)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Combination Drug Therapy (Combination Chemotherapy)
3. Immunotherapy
4. Laparotomy
5. Adjuvant Chemotherapy